Prospective Study of Biotin Treatment in Patients With Erythema Due to Gefitinib or Erlotinib
This study examined biotin as a treatment for skin rashes caused by EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, in patients with non-small cell lung cancer (NSCLC). Four patients who were unresponsive to steroid treatments showed improvement after taking biotin, with two able to continue EGFR-TKI therapy.
June 26, 2025
No Comments